Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 313

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 313
---
, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches, or
interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any
such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties,
publicly disclosed, lost or stolen. We have measures in place that are designed to prevent, and if necessary to detect and respond to
such security incidents, breaches of privacy, and security mandates. However, in the future, any such access, disclosure or other loss
of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such
as HIPAA in the United States and the General Data Protection Regulation in the European Union, or GDPR, government enforcement actions
and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process
samples, provide test results, share and monitor safety data, bill payers or patients, provide customer support services, conduct research
and development activities, process and prepare company financial information, manage various general and administrative aspects of our
business and may damage our reputation, any of which could adversely affect our business, financial condition and results of operations.

Geopolitical
events and global economic conditions, such as the Israel-Hamas war may impact the third parties that we engage to supply materials or
manufacture any products for our preclinical tests and clinical trials, which increases the risk of potential delay of development efforts,
as applicable.

If
the third parties that we engage to supply any materials or manufacture any products for our preclinical tests and clinical trials should
cease to continue to do so for any reason, including due to the effects of global economic conditions, including the Hamas-Israel war,
we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers,
as applicable, and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able
to obtain adequate supplies of our product, or the substances used to manufacture them, it will be more difficult for us to develop our
product and compete effectively.

Our
current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop our product, and product candidates
and could delay our clinical trials and development programs as well as affect our marketing and commercialization efforts. In addition,
such dependence may increase our costs and